We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Radcal

Medtronic

Medtronic offers medical products and therapies for the treatment of cardiac and vascular diseases, diabetes, and neu... read more Featured Products: More products

Download Mobile App




First-Of-Its-Kind Implantable Defibrillator Technology Treats Abnormal Heart Rhythms and Sudden Cardiac Arrest

By HospiMedica International staff writers
Posted on 24 Oct 2023
Print article
Image: The Aurora EV-ICD system has received FDA approval to treat abnormal heart rhythms and sudden cardiac arrest (Photo courtesy of Medtronic)
Image: The Aurora EV-ICD system has received FDA approval to treat abnormal heart rhythms and sudden cardiac arrest (Photo courtesy of Medtronic)

Implantable cardioverter-defibrillators (ICDs) play a crucial role in saving lives by treating patients at risk of sudden cardiac arrest (SCA), which can be fatal if not addressed immediately. SCA is usually caused by a rapid heartbeat or an irregular heart rhythm. Traditional ICDs are typically inserted beneath the collarbone, and their leads run through the veins directly into the heart. Now, a first-of-its-kind ICD system offers a single device and single procedure with the lead positioned outside the heart and veins to minimize the risk of long-term complications.

Medtronic plc (Dublin, Ireland) has received U.S. Food and Drug Administration (FDA) approval for the Aurora EV-ICD MRI SureScan (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV MRI SureScan defibrillation lead to treat dangerously fast heart rhythms that can lead to SCA. This is the first system of its kind to offer the benefits of conventional ICDs while placing the lead beneath the breastbone, outside of the heart and veins. The Aurora EV-ICD has a form factor, size, and lifespan similar to traditional ICDs that utilize leads passing through the veins.

In contrast to conventional ICDs, the Aurora EV-ICD is implanted under the left armpit and the lead is positioned under the breastbone using a less invasive method. The Epsila EV lead avoids certain complications related to traditional transvenous leads, such as damage to blood vessels or obstructions. The device provides essential defibrillation, anti-tachycardia pacing (ATP), and back-up pacing therapies, similar to those available in standard Medtronic transvenous ICDs. The FDA has approved the Aurora EV-ICD system along with its specialized implantation tools, supported by pivotal global trials proving its safety and effectiveness.

The pivotal study revealed a 98.7% effectiveness rate for the device's defibrillation capabilities at the time of implantation. Furthermore, neither any significant complication was observed during the procedure, nor any unique complication when compared to traditional and subcutaneous ICDs. Importantly, the ATP feature prevented 33 unnecessary defibrillation shocks, and 92.6% of patients remained free from the major system or procedure-related complications, like hospitalization or death, six months post-implantation. The Aurora EV-ICD system will soon be available commercially in the U.S. on a restricted basis. Those who receive the device will also benefit from the inclusion of Smart Sense, a unique algorithm designed to reduce the likelihood of inappropriate shocks.

"This FDA approval paves the way for patients to have a better overall experience with ICD therapy," said Alan Cheng, M.D., chief medical officer of the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic. "ICDs remain the gold standard for prevention of sudden cardiac death, and while the subcutaneous ICD avoids certain complications associated with transvenous defibrillators, it has limitations that may affect a patient's comfort and quality-of-life. With the Aurora EV-ICD system, patients can benefit from the only ICD placed outside the vascular space that provides ATP and back-up pacing, in a device that is nearly half the size and with 60% greater projected battery longevity compared to the competitor's subcutaneous ICD."

Related Links:
Medtronic plc 


Print article

Channels

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: POCT offers cost-effective, accessible, and immediate diagnostic solutions (Photo courtesy of Flinders University)

POCT for Infectious Diseases Delivers Laboratory Equivalent Pathology Results

On-site pathology tests for infectious diseases in rural and remote locations can achieve the same level of reliability and accuracy as those conducted in hospital laboratories, a recent study suggests.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.